Role of Wnt signalling in advanced prostate cancer

Revisiting the role of Wnt/β-catenin signaling in prostate cancer

(2018) Jeffrey A. Schneider et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis

(2017) Matthew T Jefferies et al.   JOURNAL OF PATHOLOGY

Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials

(2016) Benjamin Lu et al.   Cancers

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Can we safely target the WNT pathway?

(2014) Michael Kahn   NATURE REVIEWS DRUG DISCOVERY

Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)

(2013) Arnoud J. Templeton et al.   EUROPEAN UROLOGY

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer

(2011) I. Ahmad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer

(2008) Robert J. Amato et al.   Clinical Genitourinary Cancer

Many roads lead to oncogene-induced senescence

(2008) S Courtois-Cox et al.   ONCOGENE